ABCSG (@ABCSGVienna) header
ABCSG (@ABCSGVienna) profile picture
Wien
Joined September 2013
Photo by ABCSG (@ABCSGVienna)Photo by ABCSG (@ABCSGVienna)Photo by ABCSG (@ABCSGVienna)Photo by ABCSG (@ABCSGVienna)Photo by ABCSG (@ABCSGVienna)Photo by ABCSG (@ABCSGVienna)Photo by ABCSG (@ABCSGVienna)Photo by ABCSG (@ABCSGVienna)Photo by ABCSG (@ABCSGVienna)Photo by ABCSG (@ABCSGVienna)
🔬 New publication Long-term follow-up and high-quality biospecimens from clinical trials provide a unique foundation for translational cancer research. A new study highlights the value of samples from #ABCSG-8 in advancing biomarker research in early breast cancer.
1
107
The study validated the prognostic performance of the Xpert Breast Cancer Insight (BC Insight) Test in ER-positive, HER2-negative early breast cancer. The test was shown to predict distant recurrence and overall survival, supporting biomarker-based risk assessment.
1
47
This publication demonstrates how well-characterized clinical trial cohorts continue to generate scientific insights beyond their original objectives – contributing to the advancement of precision oncology. 📖 doi.org/10.1016/j.clbc.2026.… #TranslationalResearch #PrecisionOncology
17
📘 #ABCSG Annual Report 2025 is now online! A highly productive year for the ABCSG is now summarized in our new Annual Report. 🔬 👉 Full report: abcsg.org/wp/wp-content/uplo…
1
52
The Annual Report also highlights key developments in: ▪️ Clinical research ▪️ Translational projects ▪️ International collaborations ▪️ Education & training activities
1
20
We sincerely thank all investigators, study nurses and study coordinators, patients, and team members of the trial office for their continued commitment. 🤝 👉 Full report: abcsg.org/wp/wp-content/uplo…
35
Clinical research, precision medicine & AI are rapidly transforming care - but how can these advances be implemented across diverse healthcare systems while accounting for clinical heterogeneity?
1
11
💬 “Our goal must be to align global standards with regional realities in order to ensure the best possible care for all patients.” so @MichaelGnant #ABCSGbefirst #BreastCancer #CancerResearch #ClinicalTrials #Oncology #PrecisionMedicine #GlobalHealth 🧬
15
🔬 Long-term follow-up from #ABCSG-34 shows: Baseline ctDNA positivity in early breast cancer is associated with less favorable survival outcomes. ➡️ Supporting ctDNA as a prognostic biomarker #ctDNA #Biomarkers #CancerResearch
1
44
🧪 Findings also highlight: • Potential of ctDNA monitoring during neoadjuvant therapy • Importance of long-term translational research 👏 Thanks to all investigators & collaborators! #TranslationalResearch #ClinicalTrials #NeoadjuvantTherapy
15
Important guidance for #BreastCancer in the context of the Austrian treatment landscape 🇦🇹 New publication in #WienerKlinischeWochenschrift: 👉 “Austrian treatment algorithms 2025: CDK4/6 inhibitors in the adjuvant therapy of HR+/HER2– early breast cancer” @MichaelGnant
1
60
#CancerWorld magazine features @MichaelGnant, President of the Austrian Breast & Colorectal Cancer Study Group #ABCSG. 📖 Issue 113 (03/2026) 🔗 abcsg.org/wp/wp-content/uplo…
1
1
2
104
The profile highlights his work challenging overtreatment, advancing international clinical trials, and shaping the future of oncology - a thoughtful portrait of a physician-scientist challenging established routines. #ABCSGbefirst #BreastCancer #Oncology #ClinicalTrials
1
37